EGFR and colonic neoplasm: We provided evidence that colon cancer patients harboring the BRAF(V600E) oncogenic mutation were lack a significant response to PLX4720, but BRAF and EGFR inhibition can be synergistic when combined, suggesting more combining targeted agents can be used in clinical trials.